Characteristics | Ascend group (n, %) | Stable group (n, %) | P |
---|---|---|---|
Gender | Â | Â | 0.346 |
 Male | 30 (49.2) | 7 (36.8) |  |
 Female | 31 (50.8) | 12 (63.2) |  |
Age (median, range) | 62 (40~84) | 69 (40~84) | 0.362 |
Body weight loss | Â | Â | 1.000 |
 <5 % | 58 (95.1) | 19 (100.0) |  |
 ≥5 % | 3 (4.9) | 0 (0.0) |  |
Smoking status | Â | Â | 0.401 |
 Never-smokers | 41 (67.2) | 15 (78.9) |  |
 Smokers | 20 (32.8) | 4 (21.1) |  |
ECOG PS | Â | Â | 1.000 |
 0~1 | 58 (95.1) | 18 (94.7) |  |
 ≥2 | 3 (4.9) | 1 (5.3) |  |
Pathology | Â | Â | 1.000 |
 Adenocarcinoma | 58 (95.1) | 18 (94.7) |  |
 Non-adenocarcinoma | 3 (4.9) | 1 (5.3) |  |
Clinical stage | Â | Â | 1.000 |
 IIIB | 1 (1.6) | 0 (0.0) |  |
 IV | 60 (98.4) | 19 (100.0) |  |
Line of EGFR-TKI | Â | Â | 0.371 |
 First-line | 36 (59.0) | 9 (47.4) |  |
 ≥Second-line | 25 (41.0) | 10 (52.6) |  |
EGFR-TKI | Â | Â | 0.946 |
 Erlotinib | 23 (37.7) | 7 (36.8) |  |
 Gefitinib | 38 (62.3) | 12 (63.2) |  |
Basic level of plasma L858R mutation (median, range) | 20.0 (0.97~109.43) | 27.45 (3.56~112.9) | 0.184 |